[go: up one dir, main page]

AU2001269439A1 - Medicinal preparations for treating sex hormone-dependent diseases - Google Patents

Medicinal preparations for treating sex hormone-dependent diseases

Info

Publication number
AU2001269439A1
AU2001269439A1 AU2001269439A AU6943901A AU2001269439A1 AU 2001269439 A1 AU2001269439 A1 AU 2001269439A1 AU 2001269439 A AU2001269439 A AU 2001269439A AU 6943901 A AU6943901 A AU 6943901A AU 2001269439 A1 AU2001269439 A1 AU 2001269439A1
Authority
AU
Australia
Prior art keywords
sex hormone
dependent diseases
medicinal preparations
treating sex
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269439A
Inventor
Yasutaka Igari
Shigeru Kamei
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU2001269439A1 publication Critical patent/AU2001269439A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001269439A 2000-07-05 2001-07-04 Medicinal preparations for treating sex hormone-dependent diseases Abandoned AU2001269439A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000208253 2000-07-05
JP2000-208253 2000-07-05
PCT/JP2001/005808 WO2002002144A1 (en) 2000-07-05 2001-07-04 Medicinal preparations for treating sex hormone-dependent diseases

Publications (1)

Publication Number Publication Date
AU2001269439A1 true AU2001269439A1 (en) 2002-01-14

Family

ID=18704873

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269439A Abandoned AU2001269439A1 (en) 2000-07-05 2001-07-04 Medicinal preparations for treating sex hormone-dependent diseases

Country Status (5)

Country Link
US (2) US20030176360A1 (en)
EP (1) EP1297850B1 (en)
AU (1) AU2001269439A1 (en)
CA (1) CA2412899C (en)
WO (1) WO2002002144A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087616A1 (en) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Preventives for postoperative recurrence of premenopausal breast cancer
US7087686B2 (en) 2001-08-06 2006-08-08 Bp Chemicals Limited Chain growth reaction process
EP1424080B1 (en) * 2001-08-10 2011-02-16 Takeda Pharmaceutical Company Limited Gnrh agonist combination drugs
EP1479684A4 (en) 2002-01-30 2006-01-04 Takeda Pharmaceutical THIENOPYRIMIDINES, PROCESS FOR THEIR PRODUCTION AND THEIR USE
SI1591446T1 (en) 2003-01-29 2013-07-31 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US8211856B2 (en) 2007-09-11 2012-07-03 Mondobiotech Laboratories Ag Use of somatostatin-14 as a therapeutic agent
EP2780012A4 (en) * 2011-11-18 2015-07-29 Apotex Technologies Inc TREATMENT PROCEDURE WITH DEFERIPRON

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (en) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
JPH0720859B2 (en) 1985-02-07 1995-03-08 武田薬品工業株式会社 Microcapsule manufacturing method
US4705778A (en) * 1985-10-22 1987-11-10 Sri International Orally active LHRH analogs
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US4761398A (en) * 1986-08-18 1988-08-02 Embrex, Inc. Method of inducing birds to molt
WO1989007451A1 (en) 1988-02-10 1989-08-24 Abbott Laboratories Reduced size lhrh analogs
US5110904A (en) 1989-08-07 1992-05-05 Abbott Laboratories Lhrh analogs
US4992421A (en) * 1988-04-19 1991-02-12 Abbott Laboratories Luteinizing hormone releasing hormone antagonist
US5171835A (en) * 1988-10-21 1992-12-15 The Administrators Of The Tulane Educational Fund LHRH antagonists
US5258492A (en) * 1988-10-21 1993-11-02 The Administrators Of The Tulane Educational Fund LHRH analogues with cytotoxic moieties at the sixth position
US5130137A (en) * 1989-08-09 1992-07-14 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
JP2653255B2 (en) 1990-02-13 1997-09-17 武田薬品工業株式会社 Long-term sustained release microcapsules
JP2719233B2 (en) * 1991-04-25 1998-02-25 デゲンギ，ロマノ Luteinizing hormone-releasing hormone antagonist peptide
JP3277342B2 (en) 1992-09-02 2002-04-22 武田薬品工業株式会社 Manufacturing method of sustained release microcapsules
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
JPH08259460A (en) 1995-01-23 1996-10-08 Takeda Chem Ind Ltd Production of sustained release pharmaceutical preparation
US5574011A (en) * 1995-04-04 1996-11-12 Tien; Henry C. Compositions and methods for the treatment of male-pattern baldness
JP3902272B2 (en) 1995-09-04 2007-04-04 武田薬品工業株式会社 Manufacturing method of sustained-release preparation
JP3765338B2 (en) 1995-12-15 2006-04-12 武田薬品工業株式会社 Manufacturing method of sustained-release preparation for injection
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
DE19604231A1 (en) * 1996-01-29 1997-07-31 Schering Ag Combined pharmaceutical preparation and its use for the treatment of gynecological disorders
AU2407997A (en) 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
EP1048301A4 (en) 1998-01-16 2005-03-09 Takeda Chemical Industries Ltd CONTROLLED RELEASE COMPOSITIONS, PROCESS FOR THEIR MANUFACTURE AND USE
JP4536837B2 (en) 1998-01-21 2010-09-01 武田薬品工業株式会社 Manufacturing method of sustained-release preparation
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers

Also Published As

Publication number Publication date
EP1297850A1 (en) 2003-04-02
US20080207524A1 (en) 2008-08-28
EP1297850B1 (en) 2015-08-19
CA2412899C (en) 2010-11-09
CA2412899A1 (en) 2002-12-12
EP1297850A4 (en) 2005-04-13
US20030176360A1 (en) 2003-09-18
WO2002002144A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
HUP0301815A3 (en) Mono and disaccharide-based pharmaceutical composition for infections and other diseases and prophylactic and therapeutic treatment
CZ20011229A3 (en) Ophthalmological preparations
AU2002252152A1 (en) Tissue electroperforation for enhanced drug delivery and sampling
AU2002212695A1 (en) Remedies for arachidonic acid-induced skin diseases
IL196301A0 (en) Medicament for the treatment of hapatitis c
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
AU2002239491A1 (en) Methods for the treatment of cancer and other diseases and methods of developing the same
AU2000265525A1 (en) Medicament for treating intestinal diseases
AU2001233208A1 (en) Human sulfatases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU7731700A (en) Low dose ifn-gamma for treatment of disease
AU2001232787A1 (en) Airway alkalinization as therapy for airway diseases
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
AU2000279614A1 (en) Remedies for endothelin-induced diseases
AU2001243515A1 (en) Combination drug therapy
AU2001269439A1 (en) Medicinal preparations for treating sex hormone-dependent diseases
AU2001232335A1 (en) Skin preparations for external use
IL151188A0 (en) Medicament for viral diseases
AU2002221760A1 (en) Vaccine for treating allergy
AU2001271026A1 (en) Remedies for bone diseases
AU2001228863A1 (en) Remedies for ophthalmic diseases
AU2000263936A1 (en) Substance p analogs for the treatment of cancer
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases
AU2001274446A1 (en) Vip-related peptides for the treatment of skin disorders
AU6106801A (en) Trans-clitoral administration of therapy